SHENZEN, China, March 20 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS) www.htdsmedical.com is pleased to announce that the first batch of Influenca Vaccine (MEVAC-FLU) entered Chilean market. The company will also attend the tender of 2.5 million doses of influenza vaccine for Chile in 2009.
Terry Yuan CEO of HTDS said, "After two years of hard work, we have finished the registration of the influenza vaccine in Chile. The ISP (Instituto De Salud Publica de Chile) issued the GMP certificate to our plant after a strict inspection in June, 2008. In Dec. 2008, we obtained the registration certificate successfully. Now, in Feb.2009, we have exported the first lot of 25,000 units of influenza vaccine (Brand name: Mevac Flu) to Chile. This is the first time for Chinese influenza vaccine to enter the Chilean market. We see this as a good opportunity to open up the South American market for us as a company.
"The Chilean government has a tender project each year for influenza vaccine of 1.5-2.7 million doses. This is a free vaccination for the elder people. In Sep. 2009, Mellow Hope will participate to bid the tender of 2.5 million doses. Since the first lot is being used by the local people, once the vaccine is well-approved, it will be helpful for Mellow Hope to bid the tender."
The company will provide further details as they become available.
Get the Facts Right. The issuer works hard to continue to keep our shareholders informed, and news is updated frequently via Press Releases, Pink Sheet http://www.pinksheets.com/ filings, and updates to our websites. Other websites not sponsored, or recognized by the Company may provide misleading or disinformation to investors in order to manipulate trading patterns for a given stock. Always look for original content from trusted sources, rather than relying on 'excerpts' or discussion boards that may not give you the whole story. The Securities and Exchange Commission requires financial institutions or brokerage firms to provide their clients with documentation, describing the risks of investing in penny stocks.
CONTACT: For medical and scientific dialogue inquiry only, please contact Andrea Zecevic Hbsc. Msci via e-mail at azconsulting2001@gmail.com. Andrea Zecevic obtained her degrees at the University of Toronto Canada. Andrea Zecevic is the company's Chief Project Scientist, R&D and the Chief Liaison Director between the China and Serbia operating subsidiaries. For any corporate matters, readers should contact the company directly at corporate@htdsmedical.com
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment